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ABSTRACT 
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a serious medical condition affecting 
over 12% of Americans and is associated with $58 billion in work-related annual costs. 
Prediabetes increases risk for T2DM, and is estimated to affect over one third of U.S. adults. 
There is an evident need to prevent the development of T2DM in at-risk individuals. Adults 
spend a significant portion of their time at the workplace, suggesting its utility for efforts at 
health promotion and disease prevention. The Diabetes Prevention Program (DPP) is a lifestyle 
intervention program that has demonstrated efficacy in preventing or delaying T2DM in at-risk 
adults, however there is a lack of well-designed research studies evaluating the efficacy of the 
DPP in the workplace. The primary aim of this study was to implement and evaluate the efficacy 
of the group-based DPP intervention at The Ohio State University (OSU). 
 
METHODS: Seventy-eight employees with prediabetes recruited from OSU were randomized to 
the 16-week group-based DPP intervention group or a usual care control group. Sixty-eight 
participants completed data collection at baseline and post-intervention. Clinical and 
anthropometric measures included body weight, waist circumference, fasting blood glucose and 
lipids, and blood pressure. Statistical analyses included Pearson chi-square tests for baseline 
demographic characteristics and Student t-tests within an ANOVA for between and within-group 
analyses. For data not meeting normality assumptions, Wilcoxon signed rank tests were used for 
within-group and Wilcoxon rank sum 2-sample test for between-group comparisons. 
Multivariate analyses between variables were completed using Spearman nonparametric 
correlations. 
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RESULTS: There were no significant differences in primary outcomes between treatment groups 
at baseline except for occupation. Mean (±SE) change in body weight for experimental versus 
control groups was -5.25 kg (±0.55) vs. -0.37 kg (±0.56), (p<0.0001). Fasting glucose was 
reduced by a mean (±SE) of -8.56 mg/dL (±1.52) and -4.48 mg/dL (±1.79), (p=0.0293), for the 
experimental versus control groups, respectively.  
 
CONCLUSIONS: The worksite was an effective setting to implement the DPP intervention, and 
facilitated significant reductions in body weight and blood glucose. Evaluation of cost-
effectiveness of the intervention for employers and long-term maintenance of weight loss and 
prevention of T2DM are warranted.  
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INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is a major medical concern in the U.S. that has 
increased at alarming rates in recent decades.  National Health and Nutrition Examination Survey 
(NHANES) data indicates there has been an estimated relative increase of 45% in combined 
diagnosed & undiagnosed T2DM from 1988-1994 to 2005-2010, with the present estimated 
prevalence at 12.1%.1  Undiagnosed T2DM has been shown to comprise 19-40% of diabetes 
cases, suggesting that there is a growing need for T2DM screening and prevention efforts.2-4   
With rates continuing to increase, there are numerous fiscal and social costs associated 
with T2DM.  The total national cost of diabetes in the U.S. in 2007 was estimated at $174 
billion, with $58 billion in reduced productivity from work-related absenteeism, reduced 
productivity at work and at home, unemployment from chronic disability, and premature 
mortality.5  There is reported to be an annual incremental cost to employers of $4413 for 
employees with T2DM compared to those without T2DM, and greater than 30% of costs 
associated with diabetic employees are attributable to medically related work absences and 
disability.6  The American Diabetes Association (ADA) reports that of the roughly 16 million 
people in 2007 who were unemployed or on disability, over 1 million had T2DM and over 
445,000 cases of unemployment were attributed to T2DM, resulting in a total of 107 million lost 
work days at a national cost of $7.9 billion.5  In addition to national and employer fiscal costs, 
there are also fiscal costs incurred by individuals with T2DM.  About half of all doctor office, 
emergency, and hospital outpatient visits in addition to outpatient prescriptions incurred by 
people with T2DM are attributable to their diabetes.5  Beyond fiscal costs, T2DM also imposes 
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unquantifiable costs on society in terms of reduced quality of life as well as pain and suffering 
experienced by people with T2DM and their family.5   
An increased risk for developing T2DM is associated with prediabetes, obesity, and lack 
of physical activity.7-10  Prediabetes is defined as having impaired fasting plasma glucose levels 
of 100-125 mg/dl, impaired glucose tolerance following 2-hour oral glucose tolerance test with 
plasma glucose levels of 140-199 mg/dl, or hemoglobin A1c of 5.7-6.5%.7  NHANES data 
indicates that there has been a significant increase in prediabetes prevalence for adults from 
30.2% in 1999-2002 to 36.5% in 2007-2010.11  It has been reported that prediabetes itself is 
associated with greater prevalence of microvascular and macrovascular complications that are 
commonly associated with T2DM.12-15  Additionally, among full-time employees in the U.S., 
obesity-related medical costs are estimated at $73.1 billion, with $30.0 billion attributable to 
presenteeism, $12.8 billion attributable to absenteeism, and $30.3 billion attributable to medical 
expenditures.16, 17  With prediabetes rates on the rise and costs associated with obesity and 
T2DM well documented, there is an evident need for continued efforts to prevent the 
development of T2DM in at-risk individuals.  
Numerous randomized control trials in multiple countries have demonstrated the efficacy 
of intensive lifestyle interventions in preventing or delaying the development of T2DM in at-risk 
populations.8, 18-20  The lifestyle interventions have primarily focused on achieving weight loss 
through improving dietary habits and increasing physical activity levels.  Results from the 
Diabetes Prevention Program (DPP), which is a goal-based individual behavioral intervention 
providing nutrition and physical activity education and emphasizing self-monitoring, indicate 
that weight loss through intensive lifestyle intervention is more effective in reducing incidence of 
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T2DM in adults with prediabetes than pharmacotherapy, although both are effective 
interventions.8  For every kilogram of weight loss achieved in the DPP, there was found to be a 
16% reduction in diabetes risk, adjusting for changes in diet and activity.21  Ten-year follow-up 
of participants in the DPP showed that diabetes incidence was lowest for participants in the 
lifestyle intervention group.22  
Adults spend a significant portion of their time at work, which makes the worksite an 
ideal setting to provide opportunities for health promotion and disease prevention for employees.  
There has recently been increasing interest among employers to provide programs at the worksite 
that are focused on improving the health of employees.   Employers have an incentive to offer 
wellness programs, as the potential exists for cost-savings if employees’ medical costs and 
absenteeism are reduced through improvements to their health.  Reviews of studies evaluating 
worksite programs for weight loss and obesity prevention have revealed evidence of success.23-25  
There is strong evidence of the efficacy of weight reduction through worksite health promotion 
programs aimed at improving nutrition, physical activity, or both.24  The workplace can be a 
unique setting to identify individuals at risk for developing T2DM and provide opportunities to 
reduce their risk while also saving employers the potential future costs they could incur if those 
employees develop T2DM.6   
There have been recent translations of the DPP to a variety of community settings such as 
churches, hospitals, and worksites.26, 27  While many of these settings have been shown to be 
effective for the general community, few studies have examined the efficacy of implementing the 
DPP in the worksite.26, 28-31  Adaptations to the format of the DPP intervention for utilization in 
worksites have varied, including providing the intervention via self-study, weekly group 
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sessions, one-on-one sessions, modifying the number and frequency of sessions, and a 
combination of the above.28-31  Of the articles identified that utilized the DPP for a worksite 
intervention, only one employed a randomized controlled trial study design28; one refined 
inclusionary criteria to only those at risk for T2DM29; two assessed clinical indicators of diabetes 
risk before and after the intervention28, 29; and only utilized an intervention format consistent 
with prior adaptations29.  Clearly, there is a lack of well-designed studies evaluating the efficacy 
of implementing the DPP in the worksite in efforts to improve health and reduce diabetes risk.  
 
  
8 
 
METHODS 
Research Design 
A randomized controlled trial design was utilized for this efficacy study with the purpose 
of evaluating the DPP intervention for diabetes prevention in the worksite setting at The Ohio 
State University (OSU).  Approval for the study was obtained from the Institutional Review 
Board (IRB) at OSU and all participants provided written, informed consent.  Eligible 
participants were randomized to receive either the 16-week healthy lifestyle treatment or to 
receive usual care from their health care providers, which served as the control.  Data was 
collected at baseline, post-intervention, and at 3-month follow-up.  
Sample 
 Employees were recruited for this research study between August 2012 and May 2013.  
A variety of recruitment methods were utilized, including a health fair table, letters of invitation 
through The OSU Health Plan, various advertisement formats including OSUToday, and 
recruitment websites including ResearchMatch and StudySearch.  Inclusion criteria included 
OSU employees between the ages of 18 to 65 years old with prediabetes (fasting blood glucose 
values between 100-125 mg/dl) who were overweight or obese, as defined by a BMI of 25 to 50 
kg/m2.  Exclusion criteria were established as factors that could potentially interfere with study 
participation, weight loss rates, and fasting blood sugar levels.  Participants could not have a 
current diagnosis of T2DM or type 1 diabetes mellitus (T1DM).  Participants could not be 
pregnant, breastfeeding, or trying to become pregnant for the duration of the study due to the 
changes to energy requirements and weight status associated with these states.  Participants could 
not be pursuing bariatric surgery or have recently had bariatric surgery, as weight loss rates are 
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much greater following surgery than without.  Participants also could not be participating in any 
other weight management programs as the effects of those programs could confound study 
results.  Participants could not be taking any medications that modify blood glucose levels, such 
as Metformin or steroids.  Additionally, participants could not be planning to leave their 
employment at OSU within one year of enrollment in the study.   
Intervention Group 
 The participants who were randomized to the intervention group received the manualized 
16-week DPP intervention.  Groups met either during the lunch hour or in the evening after work 
for 60 minutes each week.  A registered dietitian employed by the OSU Health Plan served as the 
interventionist for the lunch hour groups, and a registered dietitian graduate student served as the 
interventionist for the evening group.  Both interventionists completed the two-day training 
sessions for DPP lifestyle coaches conducted by Dr. David Marrero, a principal investigator with 
the original DPP intervention.  The behavioral goals for the program were consistent with those 
of the original DPP, and included achieving 7% weight loss at the end of the intervention 
program, completing at least 150 minutes per week of moderate to vigorous intensity physical 
activity, and meeting a personal recommended daily fat gram goal equivalent to 25% of total 
energy intake.8   
Participants were provided intervention materials, a Carbohydrate, Fat & Calorie Guide, and 
weekly food and exercise trackers.32  Participants received their program goals at the first 
session, and were encouraged to set smaller, specific goals each week relating to the weekly 
session topics.  They engaged in group discussions and completed individual and group activities 
each week during the 60-minute sessions, establishing support networks with their fellow group 
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members.  They were expected to track their diet and physical activity each day in their weekly 
tracker booklets and submit them each week to be reviewed by the interventionist, who returned 
them the following week with individualized feedback.  Daily self-monitoring of diet and 
physical activity allowed participants to be more accountable to their goals and receive support 
as they made changes to their lifestyles.  While missing any of the weekly group sessions was 
discouraged, efforts were made to provide individual make-up sessions and collect weight 
measurements for any participants who missed a regularly scheduled group session.  Methods 
were employed to enhance treatment fidelity for this research study.33 The principal investigator 
(PI) for the study observed >20% of intervention sessions and found no serious departures from 
the curriculum as planned.  
Control Group 
 Following randomization, participants in the control group were provided with the “Small 
Steps. Big Rewards. Your GAME PLAN to Prevent Type 2 Diabetes: Information for Patients” 
booklet that was based on the lifestyle modification strategies used in the DPP 
(http://ndep.nih.gov/publications/PublicationDetail.aspx?PubId=71).  These participants were 
advised to utilize the information in booklet on their own, and were encouraged to continue 
receiving usual care from their health care providers for the duration of the research study.  They 
were discouraged from participating in any weight management programs in order to limit 
confounding variables.  Following all data collection, participants in the control group were 
invited to attend a 1-hour session which addressed key principles to promote weight loss in the 
DPP intervention.  
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Study Measures 
 All study measures were collected at baseline, post-intervention, and at 3-month follow-
up.  Body weight was measured using a calibrated Health-O-Meter Professional® digital scale.  
Height was collected only at the initial screening visit, and was measured using a Perspective 
Enterprises® standing stadiometer.  For both height and weight, participants were measured with 
shoes and excess clothing removed. Waist circumference measurements were obtained using the 
procedure identified in the National Health and Nutrition Examination Survey (NHANES).34  All 
anthropometric measurements were collected twice at each visit and mean values were 
determined for each.  BMI (kg/m2) was calculated from mean values for body weight and height.   
 Fingerstick whole blood samples were collected from study participants after a minimum 
8-hour fast at both the initial screening and post-intervention visits.  The Alere Cholestech LDX® 
System was utilized to complete point-of-care analysis of the whole blood samples for glucose, 
total and HDL cholesterol, and triglycerides.  LDL cholesterol was calculated by the system 
using the Friedewald formula.35  The Alere Cholestech LDX® System has been certified as 
accurate and reproducible by the CDC’s Lipid Standardization Program (LSP) and Cholesterol 
Reference Method Laboratory Network (CRMLN).36  Additionally, two blood pressure readings 
were collected from seated participants at each data collection visit with an Omron Healthcare, 
Inc. 7-SeriesTM home blood pressure cuff, which meets the protocol criteria for validation 
standards of the European Society of Hypertension (ESH).37  
Statistical Analysis 
Baseline demographic characteristics were assessed using Pearson chi-square tests for 
categorical data.  The continuous variable age was assessed using a 2-sample t-test.  
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Anthropometric and clinical outcome variables with normally distributed residuals were assessed 
using student t-tests within an ANOVA for between group comparisons of mean values at 
baseline, and between group and within-group change from baseline to post-intervention.  The 
clinical outcome variables glucose, HDL cholesterol, and triglycerides had residuals that were 
not normally distributed, and were assessed using Wilcoxon Rank Sum 2-Sample tests for 
between group comparisons at baseline and between-group change from baseline to post-
intervention. Wilcoxon Signed Rank Tests were used for within-group changes from baseline to 
post-intervention for these variables. Multivariate analyses of correlation between variables were 
completed using Spearman nonparametric tests.  Statistical analyses were completed using SAS 
JMP® Pro (version 10.0.2, 2012, SAS Institute, Cary, NC).  P-values of < 0.05 were used for 
statistical significance.   
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RESULTS 
A total of 440 individuals expressed initial interest in the research study, 236 of which 
were screened over the phone for potential eligibility (see figure 1).  In-person screening 
appointments were completed by 160 potentially eligible individuals, and 78 met inclusion 
criteria and were enrolled in the study.  Random assignment allocated 40 participants to the 
intervention group and 38 to the control group.  Post-intervention data were obtained for 68 
participants (34 in each group), indicating 87% retention.   
Figure 1. Consort Flow Diagram 
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 Baseline results 
Baseline demographic information is reported in Table 1.  There were no significant 
differences between groups at baseline for demographic characteristics except occupation 
category.  All remaining baseline comparisons of intervention and control groups are shown in 
tables 3 and 4.  For anthropometric and clinical outcomes, only diastolic blood pressure 
approached significance at baseline (p=0.0571) (see table 3).  
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Table 1. Demographic characteristics of participants by treatment group at baseline 
 Experimental Group (n=34) Control Group (n=34)  
Mean (± SD) Mean (± SD) P-value 
Age (years) 51.71 (±9.63) 51.00 (±8.07) 0.7442 
 n (%) n (%) P-value 
Race  
    White 
    Non-White (Black and Asian) 
 
27 (79.41) 
7 (20.59) 
 
30 (88.24) 
4 (11.76) 
 
0.3232 
Ethnicity  
    Non-Hispanic/Latino 
    Hispanic/Latino 
 
34 (100.00) 
0 (0.00) 
 
33 (97.06) 
1 (2.94) 
 
0.3137 
Gender  
    Male 
    Female 
 
7 (20.59) 
27 (79.41) 
 
7 (20.59) 
27 (79.41) 
 
1.0000 
Education  
    Less than Bachelor’s Degree 
    Bachelor’s Degree 
    Advanced Degree 
 
14 (41.18) 
11 (32.35) 
9 (26.47) 
 
9 (26.47) 
12 (35.29) 
13 (38.24) 
 
0.3950 
Employment  
    Full-time 
    Part-time 
 
31 (91.18) 
3 (8.82) 
 
33 (97.06) 
1 (2.94) 
 
0.3026 
Marital Status  
    Married 
    Not Married  
 
24 (70.59) 
10 (29.41) 
 
26 (76.47) 
8 (23.53) 
 
0.5825 
Occupation a 
    Professional 
    Clerical 
    Other (i.e. clinical, technology,  
               physical labor) 
 
12 (36.36) 
10 (30.30) 
11 (33.33) 
 
19 (55.88) 
13 (38.24) 
2 (5.88) 
 
0.0167 
Years at Current Job 
    1-5 years 
    6-10 years 
    11-15 years 
    20+ years 
 
13 (38.24) 
12 (35.29) 
3 (8.82) 
6 (17.65) 
 
11 (32.35) 
7 (20.59) 
6 (17.65) 
10 (29.41) 
 
0.3230 
Current Student  
    No 
    Yes, full-time student 
    Yes, part-time student 
 
30 (88.24) 
2 (5.88) 
2 (5.88) 
 
32 (94.12) 
0 (0.00) 
2 (5.88) 
 
0.3562 
Number of people at home  
    1 
    2 
    3 
    4 
    5+ 
 
5 (14.71) 
17 (50.00) 
5 (14.71) 
5 (14.71) 
2 (5.88) 
 
2 (5.88) 
16 (47.06) 
5 (14.71) 
9 (26.47) 
2 (5.88) 
 
0.6520 
Annual Household Income a 
    $20,000-39,999 
    $40,000-59,999 
    $60,000-79,999 
    $80,000-99,999 
    ≥$100,000 
 
7 (21.21) 
4 (12.12) 
6 (18.18) 
9 (27.27) 
7 (21.21) 
 
3 (8.82) 
4 (11.76) 
6 (17.65) 
6 (17.65) 
15 (44.12) 
 
0.2777 
a One participant in intervention group did not provide this information 
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Between-group comparisons and outcomes 
 The experimental group had significantly greater decreases in body weight, BMI, waist 
circumference, fasting blood glucose, and blood pressure than the control group (see table 3).  
When divided by sex, change in body weight and BMI were not significantly different between 
men but remained significant between women in the experimental and control groups, and 
change in waist circumference was not significantly different between women but remained 
significant between men in the experimental and control groups.  More participants in the 
experimental than control groups lost at least 5% of their body weight following the intervention 
(p<0.0001) (see table 2).  There was no significant difference between groups in the change in 
total, HDL and LDL cholesterol, and triglycerides.  For clinical outcomes, LDL and total 
cholesterol were both significantly lower post-intervention compared to baseline within the 
experimental group (see table 3).  Within the control group, glucose was the only post-
intervention clinical outcome found to be significantly different from baseline. 
 
Table 2. Post-intervention percent weight change 
 Intervention Group (n=34) Control Group (n=33) 
Weight Loss (%) n (%) n (%) 
≤ 0% 2 (5.88) 17 (51.52) 
0 – 4.9% 14 (41.18) 15 (45.46) 
5 – 6.9% 7 (20.59) 0 (0.00) 
7 – 9.9% 7 (20.59) 0 (0.00) 
≥ 10% 4 (11.77) 1 (3.03) 
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Table 3. Mean (± SE) value and change in anthropometric & clinical outcomes by treatment group and time point 
 Baseline (T1) Post-Intervention (T2)a Change Scores (T2-T1) 
Experimental 
Group (n=34) 
Control Group 
(n=33)b P-value
c Experimental 
Group (n=34) 
Control Group 
(n=33)b 
Experimental 
Group (n=34) 
Control Group 
(n=33)b P-value
c 
Percent weight change (%) - - - - - -5.50 (±0.56) -0.35 (±0.57) <0.0001 
Body weight (kg) 95.74 (±2.93) 101.68 (±2.98) 0.1597 90.49 (±2.93)*** 101.31 (±2.98) -5.25 (±0.55) -0.37 (±0.56) <0.0001 
    Men 102.94 (±6.21) 107.44 (±6.21) 0.6175 97.23 (±6.21)** 104.44 (±6.21) -5.71 (±1.38) -2.71 (±1.38) 0.1514 
    Women 93.87 (±3.32) 100.13 (±3.38) 0.1919 88.74 (±3.32)*** 100.39 (±3.38) -5.13 (±0.57) 0.26 (±0.59) <0.0001 
BMI (kg/m2) 35.10 (±0.99) 35.94 (±1.01) 0.5572 33.20 (±0.99)*** 35.82 (±1.01) -1.91 (±0.19) -0.11 (±0.20) <0.0001 
    Men 32.22 (±1.66) 32.85 (±1.66) 0.7908 30.48 (±1.66)** 32.03 (±1.66) -1.74 (±0.41) -0.82 (±0.41) 0.1425 
    Women 35.85 (±1.14) 36.77 (±1.16) 0.5737 33.85 (±1.14)*** 36.85 (±1.16) -1.95 (±0.21) 0.08 (±0.22) <0.0001 
Waist circumference (cm) 107.27 (±2.08) 110.83 (±2.11) 0.2335 102.39 (±2.08)*** 109.63 (±2.11) -4.88 (±1.01) -1.20 (±1.02) 0.0127 
    Men 109.63 (±4.97) 109.19 (±4.97) 0.9508 102.87 (±4.97)*** 108.64 (±4.97) -6.76 (±1.23) -0.54 (±1.23) 0.0037 
    Women 106.66 (±2.33) 111.28 (±2.37) 0.1697 102.26 (±2.33)*** 109.90 (±2.37) -4.40 (±1.23) -1.38 (±1.25) 0.0919 
Glucose (mg/dL) 109.41 (±1.37) 111.64 (±1.96) 0.6422d 100.85 (±1.80)e*** 107.15 (±2.11)e* -8.56 (±1.52) -4.48 (±1.79) 0.0293d 
Total cholesterol (mg/dL) 195.74 (±4.96) 197.06 (±5.03) 0.8515 183.65 (±4.96)* 196.85 (±5.03) -12.09 (±4.73) -0.21 (±4.80) 0.0825 
LDL cholesterol (mg/dL)f 114.36 (±4.20) 113.84 (±4.26) 0.9309 104.24 (±4.25)* 115.07 (±4.32) -10.12 (±4.26) 1.22 (±4.32) 0.0662 
HDL cholesterol (mg/dL)g  50.88 (±2.35) 50.42 (±3.07) 0.3866d 50.82 (±2.00) e 49.03 (±2.54) e -0.06 (±1.73) -0.19 (±1.38) 0.9284d 
Triglycerides (mg/dL)h  166.79 (±15.11) 165.31 (±12.37) 0.7974d 160.88 (±15.28)e 161.22 (±13.38) e -8.39 (±10.14) -4.09 (±7.47) 0.8133d 
Systolic blood pressure (mmHg) 128.91 (±2.54) 124.68 (±2.58) 0.2459 120.50 (±2.54)*** 124.27 (±2.58) -8.41 (±2.22) -0.41 (±2.25) 0.0137 
Diastolic blood pressure (mmHg) 90.84 (±1.57) 86.52 (±1.60) 0.0571 82.19 (±1.57)*** 84.64 (±1.60) -8.65 (±1.23) -1.88 (±1.25) 0.0003 
 
a Student t-test within an ANOVA to compare within-group change from baseline to post-intervention; *(p<0.05); **(p<0.01); ***(p<0.001) 
b One subject excluded due to post-intervention measures collected immediately post-knee surgery while subject was on Metformin and unable to travel. 
c Student t-test within an ANOVA for between-group comparison at baseline and change from baseline to post-intervention; P-value < 0.05 used for statistical significance. 
d Wilcoxon Rank Sum 2-Sample Test for between group comparisons at baseline and between-group change from baseline to post-intervention; P-value < 0.05 used for statistical 
significance. 
e Wilcoxon Signed Rank Test for within-group comparisons from baseline to post-intervention; *(p<0.05); **(p<0.01); ***(p<0.001) 
f LDL could not be calculated due to triglycerides or HDL outside of acceptable range for one participant in each group at baseline and for two participants in each group post-
intervention. 
g HDL outside of detectable levels (>100 mg/dL) for one participant in control group post-intervention. 
h Triglycerides were below detectable levels (<45 mg/dL) for one participant in control group at baseline and for one participant in each group post-intervention.
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The percent of participants in each group who met the recommended guidelines for the 
clinical health outcomes revealed no significant differences at baseline or post-intervention 
between groups for any of the health outcomes.  However, there was a greater percentage of 
participants in the experimental than control group who met the clinical guidelines following the 
intervention (see table 4).   
Table 4. Percent of participants meeting recommended health outcomes by time point 
 Baseline Post-Intervention 
 Experimental Group (n=34) 
Control Group 
(n=33) 
 Experimental 
Group (n=34) 
Control Group 
(n=33) 
 
Optimal Health Outcome n (%) n (%) P-Value n (%) n (%) P-Value 
Glucose < 100 mg/dL 4 (11.77) 1 (3.03) 0.1738 16 (47.01) 11 (33.33) 0.2522 
Total cholesterol < 200 mg/dL 18 (52.94) 17 (51.52) 0.9070 26 (76.47) 20 (60.61) 0.1617 
LDL cholesterol < 100mg/dL 9 (26.47) 9 (27.27) 0.9410 13 (38.24) 6 (18.18) 0.0687 
HDL cholesterol > 40 mg/dL 
(men) or > 50 mg/dL (women) 17 (50.00) 14 (42.42) 0.5341 18 (52.94) 15 (45.46) 0.5400 
Triglycerides < 150 mg/dL 19 (55.88) 19 (57.58) 0.8888 19 (55.88) 15 (45.46) 0.3934 
Systolic blood pressure <120 mmHg 7 (20.59) 9 (27.27) 0.5211 16 (47.06) 11 (33.33) 0.2522 
Diastolic blood pressure < 80 mmHg 3 (8.82) 6 (18.18) 0.2614 13 (38.24) 11 (33.33) 0.6757 
 
Associations among intervention participation and changes in body weight 
 Within the experimental group, the change in body weight post-intervention was 
negatively associated with total days of self-monitoring food intake, total minutes of self-
monitoring physical activity, and total number of sessions attended during the 16-week 
intervention program (see table 5).  
Table 5. Spearman correlations among intervention attendance, self-monitoring, and 
change in body weight 
Intervention outcomes (n=32) Correlation coefficient P-Value 
Days self-monitoring food intake and change in body weight -0.6223a 0.0001 
Minutes self-monitoring physical activity and change in body weight -0.4945a 0.0040 
Total sessions attended and change in body weight -0.5997a 0.0002 
a Two subjects from experimental group completed 0 days and 0 minutes of self-monitoring, and were excluded 
from the analysis.  
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DISCUSSION & CONCLUSION  
The results from this study indicate that the 16-week group-based DPP intervention 
provided in a worksite setting was effective in reducing body weight and fasting blood glucose 
among intervention participants, which is associated with reduced risk for T2DM.8  These results 
support the DPP intervention as an effective disease risk reduction program, and provide 
promising evidence for its utility in a worksite setting.  In the present study, 32.4% of 
participants in the experimental group achieved the weight loss goal of 7% or more of body 
weight at the end of the group-based intervention (table 2), compared with 50% of participants 
who received the original 24-week one-on-one DPP intervention.8  The smaller percentage of 
participants meeting the program weight loss goal in the present study may be a result of the use 
of a shorter intervention period, in addition to less individualized attention.  Over 50% of 
participants in the experimental group for the present study successfully achieved clinically 
significant weight loss of at least 5% of their body weight, which is associated with a reduction 
in morbidity and mortality.38-40  The group-based format of the intervention was more 
appropriate for a worksite-based intervention because of the significant reduction in resources 
and time required to offer a program to multiple people at once versus individually.   
The original DPP study identified a 16% reduction in diabetes risk for every kilogram of 
body weight loss.21  The mean (±SE) post-intervention body weight loss achieved in this study 
was -5.25 kg (±0.55), comparable to the amount of weight loss achieved in the Diabetes 
Education & Prevention with a Lifestyle Intervention Offered at the YMCA (DEPLOY) 
community trial of the DPP intervention (-5.7 kg).27  Participation in the intervention program, as 
evidenced by attendance and completion of diet and physical activity self-monitoring, was 
strongly associated with post-intervention weight loss (table 5).  This association is similar to 
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that of the original DPP study, in which self-monitoring was related to achieving and sustaining 
weight loss.41  Further, the mean weight loss achieved in this study was far exceeded that of any 
of the previously examined studies using the DPP in a worksite setting (-0.94 kg to -2.58 kg).28-31  
Clearly, the DPP intervention administered in a group-based worksite setting is effective in 
producing weight loss compared to other intervention settings and formats.   
The intervention in this study was also effective in helping a greater percent of 
participants meet clinical guidelines for recommended health outcomes for glucose, lipids, and 
blood pressure compared to the standard care received by the control group (table 4).  These 
findings suggest that there may be additional health benefits of the DPP intervention beyond 
diabetes prevention when provided to individuals in a worksite setting.  An evaluation of the 
DPP on cardiovascular risk factors found that after an average of 10 years’ follow-up of 
intervention participants, there were considerable reductions for systolic and diastolic blood 
pressure, LDL cholesterol and triglycerides, and an increase for HDL cholesterol.42     
The cost-effectiveness and sustainability of worksite programs is an important 
consideration.  Ten-year follow-up data from the original DPP study found that the total 
cumulative per-participant cost of the individual lifestyle intervention was $4,601, compared to 
$769 for the placebo intervention.43  In addition, the estimated cumulative per-participant cost of 
the DPP group lifestyle intervention was $3,023, about a third the cost of the individual 
intervention.  Direct medical costs of non-intervention related medical care were also analyzed 
and found to be greater by $2,905 for the placebo compared to lifestyle intervention group.  
Future research is needed to determine whether the group-based DPP intervention is cost-
effective for U.S. employers.   
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Conclusions 
Prediabetes is a growing problem that currently affects over a third of adults in the U.S. 
and places individuals at an increased risk for developing T2DM.11   Additionally, prediabetes is 
associated with a number of costs to individuals and to employers with regards to health care and 
productivity related costs.12-17  T2DM can be delayed or prevented in at-risk adults through 
lifestyle interventions targeting weight loss such as the DPP.44  The lifestyle intervention in the 
DPP previously reduced the incidence of T2DM by 58% over a 3 year period, compared with 
placebo.8  The beneficial long-term reduction in diabetes risk following lifestyle intervention can 
persist for at least 10 years.22  The present study suggests that a worksite diabetes prevention 
program can be feasible to offer to employees without interfering with work schedules or 
productivity, and can be an effective intervention to promote improvements to employees’ health 
with a potential for long-term health implications, if results are sustained.  
Limitations 
Despite efforts to reach a diverse study population, participants in this study were 
primarily women (79.4%), and white (83.8%).  While this does not accurately represent the 
employee population at The Ohio State University, it is a common limitation of weight loss 
studies to experience difficulty recruiting men and individuals from minority populations.   
The post-intervention retention rate was 87.2%, which is comparable to that of the 
previous studies which implemented the DPP intervention (57-91% retention).28-31  Nevertheless, 
efforts to retain participants are crucial to obtaining strong study results, and thus the attrition in 
the present study is a limitation.   
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Future Directions 
Recent evidence suggests that men may benefit from gender-tailored programs with 
minimal contact.45  Further research into how best to reach these under-served populations and 
offer wellness programs that appeal to their interests and perceived needs is needed.   
In order for the group-based DPP to be adopted at a worksite, it will need to be cost-
effective, sustainable, and able to work with existing healthcare systems.  The original DPP 
intervention was found to be cost-effective from a health system and societal perspective.43  
Future research will need to evaluate the cost-effectiveness of a group-based DPP intervention in 
the worksite setting, in addition to the long-term sustainability of the program considering the 
worksite resources and systems for employee health.  The potential for diabetes prevention 
programs to be offered at the worksite exists with the recent Affordable Care Act emphasizing 
prevention and wellness through cost-effective manners in the workplace.46  
While the results from this study are promising, a larger, multi-site translational study is 
needed to further evaluate the effectiveness of the DPP intervention in the worksite.  Attempting 
to reach males and minorities will be of utmost importance in future worksite trials, and 
monitoring progression to T2DM will confirm whether or not the intervention is effective in 
reducing risk for T2DM.   
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